(VIANEWS) – MITHRA (BEL 20: MITRA.BR) experienced an astounding decline of 28.77% today in trading session; closing at EUR0.76 at 14:26 EST for the second day running and down 0.22% overall at EUR3,617.59. MITHRA’s closing price represented a drop of 73.13% from its 52-week high of EUR3.93, representing another significant negative pattern within the stock market overall.
About MITHRA
Mithra Pharmaceuticals SA is a biopharmaceutical company dedicated to developing, producing, and marketing complex therapeutics for contraception, menopause and hormone-dependent cancers. Innovation-focused, the company offers an expansive pipeline of development candidates such as Estelle (a combined oral contraceptive that has completed phase III clinical trials) and Donesta (an estetrol-based oral hormone treatment in phase III clinical trials). Mithra Pharmaceuticals SA offers products designed to aid neuroprotection and wound healing, such as Myring – a contraceptive vaginal ring releasing a combination of hormones; Tibelia – an oral tablet composed of tibolone and synthetic steroids used as menopausal hormone therapy; and Zoreline – an implant used to treat prostate, breast cancers as well as benign gynecological indications. Mithra Pharmaceuticals SA was established in 1999 and offers products in many different forms, such as polymeric forms, implants, sterile injectable products and hormonal tablets. Headquartered in Liege, Belgium it operates internationally.
Yearly Analysis
Based on the information available, MITHRA’s stock is currently trading at EUR0.76, significantly below its 52-week high of EUR1.05. This could indicate that MITHRA may be undervalued at its current price point.
MITHRA is expected to experience negative sales growth of 70.7% this year – a sharp decrease from its recent performance – though a rebound rate of 175.3% should occur over the following 12 months.
Overall, when considering MITHRA as an investment opportunity, investors may wish to examine its current stock price and sales growth projections as well as any long-term prospects or fundamentals, potential risks or challenges which could threaten its performance over the coming years.
Technical Analysis
MITHRA Pharmaceuticals of India has experienced a sharp drop in its stock price recently, falling significantly below both its 50-day moving average of EUR1.16 and 200-day moving average of EUR1.79. Nevertheless, its last reported volume (1092515) exceeded expectations by 708.08% and indicated increased trading activity.
Recent weeks have witnessed fluctuations in the stock’s volatility, with its intraday variation average fluctuating by negative 1.63%, negative 0.58% and positive 2.19% for last week, month and quarter respectively. This variability can also be seen through its highest amplitude of average volatility being 2.08% for each week; 1.28% for month; and 2.19% for quarter.
MITHRA’s stock is currently considered overbought (>=80), signalling potential oversold conditions that warrant close monitoring by investors to make investment decisions with confidence. Investors should monitor this performance closely when making financial decisions involving MITHRA shares.
Quarter Analysis
Year-on-year quarterly revenue growth has declined by 38.1% and currently stands at 62.67M for twelve trailing months.
Equity Analysis
MITHRA posted an EPS loss for its trailing 12 month period, totalling EUR-1.41 and an ROE figure of -575.59%; these indicators suggest the company isn’t producing profits efficiently and may be experiencing financial challenges that require consideration when assessing future growth potential of MITHRA. These numbers provide investors with important indicators about its financial health and future growth potential.
More news about MITHRA (MITRA.BR).
